This effect appears to be tissue-specific, as in a mouse model of RAS-driven human skin cancer, NF-κB inhibition led to tumor progression, possibly due to the role of NF-κB in a tumor’s immunogenicity [50]. The gene discussed is NFKB1; the disease is neoplasm.